Autoantibodies to glutamate receptors can damage the brain in epilepsy, systemic lupus erythematosus and encephalitis

Expert Review of Neurotherapeutics

Volumn 8, Issue 7, 2008, Pages 1141-1160

  Levite, Mia ^a,b   Ganor, Yonatan ^a,b  

^a ISR   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

AMPA; Autoimmune epilepsy; Autoimmunity; Encephalitis; Epilepsy; GluR3; Glutamate; Glutamate receptor autoantibody; Granzyme B; NMDA; SLE

Indexed keywords

AMPA RECEPTOR; AUTOANTIBODY; EXCITATORY AMINO ACID; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR 3; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; RECEPTOR ANTIBODY;

ANTIBODY PRODUCTION; AUTOIMMUNITY; BRAIN CELL; BRAIN DAMAGE; COGNITIVE DEFECT; COMPLEMENT FIXATION; CROSS REACTION; DISEASE ASSOCIATION; DISEASE SEVERITY; ENCEPHALITIS; EPILEPSY; EXCITOTOXICITY; HIPPOCAMPUS; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; NEUROTRANSMISSION; NONHUMAN; PARANEOPLASTIC NEUROPATHY; PATHOGENICITY; RASMUSSEN SYNDROME; RECEPTOR BINDING; REVIEW; SEIZURE; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; AUTOANTIBODIES; BRAIN INJURIES; ENCEPHALITIS; EPILEPSY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECEPTORS, GLUTAMATE;

EID: 46949107577     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.7.1141     Document Type: Review

References (91)

1. Danbolt NC. Glutamate uptake. Prog. Neurobiol. 65(1), 1-105 (2001).
2. Choi DW. Excitotoxic cell death. J. Neurobiol. 23(9), 1261-1276 (1992).
3. Olney JW. Excitotoxicity: an overview. Can. Dis. Wkly Rep. l6(Suppl. 1E), 47-57; discussion 57-58 (1990).
4. Ganor Y, Besser M, Ben-Zakay N, Unger T, Levite M. Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. J. Immunol. 170(8), 4362-4372 (2003).
5. Miglio G, Varsaldi F, Lombardi G. Human T lymphocytes express N-methyl-D-aspartate receptors functionally active in controlling T cell activation. Biochem. Biophys. Res. Commun. 338(4), 1875-1883 (2005).
6. Boldyrev AA, Carpenter DO, Johnson P. Emerging evidence for a similar role of glutamate receptors in the nervous and immune systems. J. Neurochem. 95(4), 913-918 (2005).
7. Ganor Y, Freilinger M, Dulac O, Levite M. Monozygotic twins discordant for epilepsy differ in the levels of potentially pathogenic autoantibodies and cytokines. Autoimmunity 38(2), 139-150 (2005).
8. Rogers SW, Andrews PI, Gahring LC et al. Autoantibodies to glutamate receptor GluR3 in Rasmussens encephalitis. Science 265(5172), 648-651 (1994).
9. Andrews PI, Dichter MA, Berkovic SF, Newton MR, McNamara JO. Plasmapheresis in Rasmussen's encephalitis. Neurology 46(1), 242-246 (1996).
10. Twyman RE, Gahring LC, Spiess J, Rogers SW. Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site. Neuron 14(4), 755-762 (1995).
11. Antozzi C, Granata T, Aurisano N et al. Long-term selective IgG immuno-adsorption improves Rasmussen's encephalitis. Neurology 51(1), 302-305 (1998).
12. Wiendl H, Bien CG, Bernasconi P et al. GluR3 antibodies: prevalence in focal epilepsy but no specificity for Rasmussen's encephalitis. Neurology 57(8), 1511-1514 (2001).
13. Mantegazza R, Bernasconi P, Baggi F et al. Antibodies against GluR3 peptides are not specific for Rasmussens encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J Neuroimmunol. 131(1-2), 179-185 (2002).
14. Baranzini SE, Laxer K, Saketkhoo R et al. Analysis of antibody gene rearrangement, usage, and specificity in chronic focal encephalitis. Neurology 58(5), 709-716 (2002).
15. Ganor Y, Goldberg-Stern H, Amromd D et al. Autoimmune epilepsy: some epilepsy patients harbor autoantibodies to glutamate receptors and dsDNA on both sides of the blood-brain barrier, which may kill neurons and decrease in brain fluids after hemispherotomy Clin. Dev. Immunol. 11(3-4), 241-252 (2004).
16. Ganor Y, Goldberg-Stern H, Lerman-Sagie T, Teichberg VI, Levite M. Autoimmune epilepsy: distinct subpopulations of epilepsy patients harbor serum autoantibodies to either glutamate/AMPA receptor GluR3, glutamate/NMDA receptor subunit NR2A or double-stranded DNA. Epilepsy Res. 65(1-2), 11-22 (2005).
17. Roubertie A, Boukhaddaoui H, Sieso V et al. Antiglial cell autoantibodies and childhood epilepsy: a case report. Epilepsia 46(8), 1308-1312(2005).
18. Feichtinger M, Wiendl H, Korner E et al. No effect of immunomodulatory therapy in focal epilepsy with positive glutamate receptor type 3-antibodies. Seizure 15(5), 350-354 (2006).
19. Solaro C, Mantegazza R, Bacigalupo A, Uccelli A. Intractable myoclonus associated with anti-GluR3 antibodies after allogeneic bone marrow transplantation. Haematologica 91(12 Suppl.), ECR62 (2006).
20. Tziperman B, Garty BZ, Schoenfeld N et al. Acute intermittent porphyria, Rasmussen encephalitis, or both? J. Child Neurol. 22(1), 99-105 (2007).
21. Carlson NG, Gahring LC, Rogers SW. Identification of the amino acids on a neuronal glutamate receptor recognized by an autoantibody from a patient with paraneoplastic syndrome. J. Neurosci. Res. 63(6), 480-485 (2001).
22. Gahring LC, Twyman RE, Greenlee JE, Rogers SW. Autoantibodies to neuronal glutamate receptors in patients with paraneoplastic neurodegenerative syndrome enhance receptor activation. Mol Med. 1(3), 245-253 (1995).
23. Gahring LC, Rogers SW, Twyman RE. Autoantibodies to glutamate receptor subunit GluR2 in nonfamilial olivopontocerebellar degeneration. Neurology 48(2), 494-500 (1997).
24. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7(11), 1189-1193 (2001).
25. Husebye ES, Sthoeger ZM, Dayan M et al. Autoantibodies to a NR2A peptide of the glutamate/NMDA receptor in sera of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 64(8), 1210-1213 (2005).
26. Omdal R, Brokstad K, Waterloo K, Koldingsnes W, Jonsson R, Mellgren SI. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur. J. Neurol. 12(5), 392-398 (2005).
27. Lapteva L, Nowak M, Yarboro CH et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum. 54(8), 2505-2514 (2006).
28. Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J. Rheumatol. 33(8), 1553-1558 (2006).
29. Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum. 54(8), 2515-2522 (2006).
30. Takahashi Y, Mori H, Mishina M et al. Autoantibodies to NMDA receptor in patients with chronic forms of epilepsia partialis continua. Neurology 61(7), 891-896(2003).
31. Takahashi Y, Mori H, Mishina M et al. Autoantibodies and cell-mediated autoimmunity to NMDA-type GluRepsilon2 in patients with Rasmussen's ncephalitis and chronic progressive epilepsia partialis continua. Epilepsia 46(Suppl. 5), 152-158 (2005).
32. Sansing LH, Tuzun E, Ko MW, Baccon J, Lynch DR, Dalmau J. A patient with encephalitis associated with NMDA receptor antibodies. Nat. Clin. Pract. Neurol. 3(5), 291-296 (2007).
33. Dalmau J, Tuzun E, Wu HY et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann. Neurol. 61(1), 25-36 (2007).
34. Okamoto S, Hirano T, Takahashi Y, Yamashita T, Uyama E, Uchino M. Paraneoplastic limbic encephalitis caused by ovarian teratoma with autoantibodies to glutamate receptor. Intern. Med. 46(13), 1019-1022(2007).
35. Iizuka T, Sakai F, Ide T et al. Anti-NMDA receptor encephalitis in Japan. Long-term outcome without tumor removal. Neurology 70(7), 504-511 (2008).
36. Nakajima H, Hosoya M, Takahashi Y et al. A chronic progressive case of enteroviral limbic encephalitis associated with autoantibody to glutamate receptor epsilon2. Eur. Neurol. 57(4), 238-240 (2007).
37. Kimura A, Sakurai T, Suzuki Y et al. Autoantibodies against glutamate receptor epsilon2-subunit detected in a subgroup of patients with reversible autoimmune limbic encephalitis. Eur. Neurol. 58(3), 152-158 (2007).
38. Mochizuki Y, Mizutani T, Isozaki E, Ohtake T, Takahashi Y Acute limbic encephalitis: a new entity? Neurosci. Lett. 394(1), 5-8 (2006).
39. Takahashi Y Infections as causative factors of epilepsy. Future Neurol. 1(3), 291-302 (2006).
40. Dambinova SA, Khounteev GA, Izykenova GA, Zavolokov IG, Ilyukhina AY, Skoromets AA. Blood test detecting autoantibodies to N-methyl-D- aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke. Clin. Chem. 49(10), 1752-1762 (2003).
41. Billiau AD, Wouters CH, Lagae LG. Epilepsy and the immune system: is there a link? Eur. J. Paediatr. Neurol. 9(1), 29-42 (2005).
42. Levite M. Autoimmune epilepsy. Nat. Immunol. 3(6), 500 (2002).
43. Rasmussen T, Olszewski J, Lloydsmith D. Focal seizures due to chronic localized encephalitis. Neurology 8(6), 435-445 (1958).
44. Watson R, Jiang Y, Bermudez I et al. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology 63(1), 43-50 (2004).
45. Bernasconi P, Cipelletti B, Passerini L et al. Similar binding to glutamate receptors by Rasmussen and partial epilepsy patients' sera. Neurology 59(12), 1998-2001 (2002).
46. Levite M, Fleidervish IA, Schwarz A, Pelled D, Futerman AH. Autoantibodies to the glutamate receptor kill neurons via activation of the receptor ion channel. J. Autoimmun. 13(1), 61-72 (1999).
47. Levite M, Hermelin A. Autoimmunity to the glutamate receptor in mice - a model for Rasmussen's encephalitis? J. Autoimmun. 13(1), 73-82 (1999).
48. Cohen-Kashi Malina K, Ganor Y, Levite M, Teichberg VI. Autoantibodies against an extracellular peptide of the GluR3 subtype of AMPA receptors activate both homomeric and heteromeric AMPA receptor channels. Neurochem. Res. 31(10), 1181-1190 (2006).
49. Frassoni C, Spreafico R, Franceschetti S et al. Labeling of rat neurons by anti-GluR3 IgG from patients with Rasmussen encephalitis. Neurology 57(2), 324-327 (2001).
50. Carlson NG, Gahring LC, Twyman RE, Rogers SW. Identification of amino acids in the glutamate receptor, GluR3, important for antibody-binding and receptor-specific activation. J. Biol. Chem. 272(17), 11295-11301 (1997).
51. Koustova E, Sei Y, Fossom L et al. LP-BM5 virus-infected mice produce activating autoantibodies to the AMPA receptor. J. Clin. Invest. 107(6), 737-744 (2001).
52. Gahring LC, Rogers SW. Autoimmunity to glutamate receptors in the central nervous system. Crit. Rev. Immunol. 22(4), 295-316 (2002).
53. Stern-Bach Y, Bettler B, Hartley M, Sheppard PO, O'Hara PJ, Heinemann SF. Agonist selectivity of glutamate receptors is specified by two domains structurally related to bacterial amino acid-binding proteins. Neuron 13(6), 1345-1357 (1994).
54. Basile AS, Koustova E, loan P, Rizzoli S, Rogawski MA, Usherwood PN. IgG isolated from LP-BM5 infected mouse brain activates ionotropic glutamate receptors. Neurobiol Dis. 8(6), 1069-1081 (2001).
55. Whitney KD, McNamara JO. GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins. J. Neurosci. 20(19), 7307-7316 (2000).
56. Wenthold RJ, Petralia RS, Blahos J II, Niedzielski AS. Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons. J Neurosci. 16(6), 1982-1989(1996).
57. Hughes T. The early history of myasthenia gravis. Neuromuscul. Disord. 15(12), 878-886 (2005).
58. Lang B, Pinto A, Giovannini F, Newsom-Davis J, Vincent A. Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome. Ann. NY Acad. Sci. 998, 187-195 (2003).
59. Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR. Phenotypic variants of autoimmune peripheral nerve hyperexcitability Brain 125(Pt 8), 1887-1895 (2002).
60. He XP, Patel M, Whitney KD, Janumpalli S, Tenner A, McNamara JO. Glutamate receptor GluR3 antibodies and death of cortical cells. Neuron 20(1), 153-163 (1998).
61. Ganor Y, Gottlieb M, Eilam R, Otmy H, Teichberg VI, Levite M. Immunization with the glutamate receptor-derived peptide GluR3B induces neuronal death and reactive gliosis, but confers partial protection from pentylenetetrazole-induced seizures. Exp. Neurol. 195(1), 92-102 (2005).
62. Ganor Y, Teichberg VI, Levite M. TCR activation eliminates glutamate receptor GluR3 from the cell surface of normal human T cells, via an autocrine/paracrine granzyme B-mediated proteolytic cleavage. J Immunol. 178(2), 683-692 (2007).
63. Takahashi Y, Matsuda K, Kubota Y et al. Vaccination and infection as causative factors in Japanese patients with Rasmussen syndrome: molecular mimicry and HLA class I. Clin. Dev. Immunol. 13(2-4), 381-387(2006).
64. Gahring L, Carlson NG, Meyer EL, Rogers SW Granzyme B proteolysis of a neuronal glutamate receptor generates an autoantigen and is modulated by glycosylation. J Immunol. 166(3), 1433-1438 (2001).
65. Anthony IC, Crawford DH, Bell JE. B lymphocytes in the normal brain: contrasts with HIV-associated lymphoid infiltrates and lymphomas. B rain 126(Pt 5), 1058-1067(2003).
66. Knopf PM, Harling-Berg CJ, Cserr HF et al. Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J. Immunol. 161(2), 692-701 (1998).
67. Loscher W Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res. 50(1-2), 105-123 (2002).
68. Hahn BH. An overview of the pathogenesis of systemic lupus erythematosus. In: Dubois' Lupus Erythematosus. Wallace DJ, Hahn BH (Eds), Williams and Wilkins, PA, USA, 69-76 (1993).
69. Winchester RJ. Systemic lupus erythematosus pathogenesis. In: Arthritis and Allied Conditions. Koopman W (Ed.), Williams and Wilkins, AL, USA, 1361-1391 (1996).
70. Arbuckle MR, McClain MT, Rubertone MV et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349(16), 1526-1533 (2003).
71. The American College of Rheumatology nomenclature and case definitions for neuropsychiatry lupus syndromes. Arthritis Rheum. 42(4), 599-608 (1999).
72. Borchers AT, Aoki CA, Naguwa SM, Keen CL, Shoenfeld Y, Gershwin ME. Neuropsychiatric features of systemic lupus erythematosus. Autoimmun. Rev. 4(6), 329-344 (2005).
73. Tomita M, Khan RL, Blehm BH, Santoro TJ. The potential pathogenetic link between peripheral immune activation and the central innate immune response in neuropsychiatric systemic lupus erythematosus. Med. Hypotheses 62(3), 325-335 (2004).
74. Hahn BH. Antibodies to DNA. N. Engl. J. Med. 338(19), 1359-1368 (1998).
75. Kowal C, DeGiorgio LA, Nakaoka T et al. Cognition and immunity; antibody impairs memory. Immunity 21(2), 179-188 (2004).
76. Huerta PT, Kowal C, DeGiorgio LA, Volpe BT, Diamond B. Immunity and behavior: antibodies alter emotion. Proc. Natl Acad. Sci. USA 103(3), 678-683 (2006).
77. Steup-Beekman G, Steens S, van Buchem M, Huizinga T Anti-NMDA receptor autoantibodies in patients with systemic lupus erythematosus and their first-degree relatives. Lupus 16(5), 329-334 (2007).
78. Shiihara T, Kato M, Konno A, Takahashi Y, Hayasaka K. Acute cerebellar ataxia and consecutive cerebellitis produced by glutamate receptor delta2 autoantibody. Brain Dev. 29(4), 254-256 (2007).
79. Shimokaze T, Kato M, Yoshimura Y, Takahashi Y, Hayasaka K. A case of acute cerebellitis accompanied by autoantibodies against glutamate receptor delta2. Brain Dev. 29(4), 224-226 (2007).
80. Granata T, Fusco L, Gobbi G et al. Experience with immunomodulatory treatments in Rasmussens encephalitis. Neurology 61(12), 1807-1810 (2003).
81. Leach JP, Chadwick DW, Miles JB, Hart IK. Improvement in adult-onset Rasmussen's encephalitis with long-term immunomodulatory therapy. Neurology 52(4), 738-742(1999).
82. Bien CG, Granata T, Antozzi C et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 128(Pt 3), 454-471 (2005).
83. Levite M, Hart IK. Immunotherapy for epilepsy. Expert Rev. Neurother. 2(6), 804-819(2002).
84. Villani F, Avanzini G. The use of immunoglobulins in the treatment of human epilepsy. Neurol. Sci. 23(Suppl. 1), S33-S37 (2002).
85. Hollmann M, Heinemann S. Cloned glutamate receptors. Annu. Rev. Neurosci. 17,31-108 (1994).
86. Boulter J, Hollmann M, O'Shea-Greenfield A et al. Molecular cloning and functional expression of glutamate receptor subunit genes. Science 249(4972), 1033-1037 (1990).
87. Keinanen K, Wisden W, Sommer B et al. A family of AMPA-selective glutamate receptors. Science 249(4968), 556-560 (1990).
88. Madden DR. The structure and function of glutamate receptor ion channels. Nat. Rev. Neurosci. 3(2), 91-101 (2002).
89. Dambinova SA, Izykenova GA, Burov SV, Grigorenko EV, Gromov SA. The presence of autoantibodies to N-terminus domain of GluR 1 subunit of AMPA receptor in the blood serum of patients with epilepsy. J. Neurol. Sci. 152(1), 93-97 (1997).
90. Degenhardt A, Duvoisin RM, Frennier J et al. Absence of antibodies to non-NMDA glutamate-receptor subunits in paraneoplastic cerebellar degeneration. Neurology 50(5), 1392-1397(1998).
91. Sillevis Smitt P, Kinoshita A, De Leeuw B et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N. Engl J. Med. 342(1), 21-27 (2000).